中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
18期
2721-2723
,共3页
尹义臣%徐武华%王幕真%张素平
尹義臣%徐武華%王幕真%張素平
윤의신%서무화%왕막진%장소평
阿尔茨海默病%多奈哌齐%阿托伐他汀%辛伐他汀
阿爾茨海默病%多奈哌齊%阿託伐他汀%辛伐他汀
아이자해묵병%다내고제%아탁벌타정%신벌타정
Alzheimer disease%Donepezil%Atrovstation%Simvastatin
目的 探讨不同类型他汀类药物联合多奈哌齐治疗阿尔茨海默病的疗效.方法 将AD患者90例采用数字表法随机分为他汀A组(阿托伐他汀+多奈哌齐治疗)31例、他汀B组(辛伐他汀+多奈哌齐治疗)27例、多奈哌齐组(单用多奈哌齐治疗)32例.三组疗程均为1年.在用药前后分别对三组患者的血脂水平[胆固醇(CH)和低密度脂蛋白胆固醇(LDL-C)]进行检测和比较,进行简易精神状态量表(MMSE)、日常生活能力量表(ADL)及全面衰退量表(GDS)的检测和评分,统计分析检测结果差异.结果 治疗后多奈哌齐组MMSE、ADL及GDS评分分别为(17.00±2.99)分、(60.44±14.57)分、(4.28±1.22)分,均差于他汀A组的[(19.90±3.07)分、(71.61 ±18.50)分、(3.39±1.15)分](t=0.218,P＜0.05,t=2.669,P＜0.01,t=2.562,P＜0.01)和他汀B组的[(19.88 ±6.66)分、(71.89±19.61)分、(3.37±1.39)分](t=1.959,P＜0.05,t =2.991,P ＜0.01,t =2.265,P＜0.01).结论 他汀联合多奈哌齐治疗AD能更有效改善AD患者的认知功能和日常生活能力,效果优于单独使用多奈哌齐.
目的 探討不同類型他汀類藥物聯閤多奈哌齊治療阿爾茨海默病的療效.方法 將AD患者90例採用數字錶法隨機分為他汀A組(阿託伐他汀+多奈哌齊治療)31例、他汀B組(辛伐他汀+多奈哌齊治療)27例、多奈哌齊組(單用多奈哌齊治療)32例.三組療程均為1年.在用藥前後分彆對三組患者的血脂水平[膽固醇(CH)和低密度脂蛋白膽固醇(LDL-C)]進行檢測和比較,進行簡易精神狀態量錶(MMSE)、日常生活能力量錶(ADL)及全麵衰退量錶(GDS)的檢測和評分,統計分析檢測結果差異.結果 治療後多奈哌齊組MMSE、ADL及GDS評分分彆為(17.00±2.99)分、(60.44±14.57)分、(4.28±1.22)分,均差于他汀A組的[(19.90±3.07)分、(71.61 ±18.50)分、(3.39±1.15)分](t=0.218,P＜0.05,t=2.669,P＜0.01,t=2.562,P＜0.01)和他汀B組的[(19.88 ±6.66)分、(71.89±19.61)分、(3.37±1.39)分](t=1.959,P＜0.05,t =2.991,P ＜0.01,t =2.265,P＜0.01).結論 他汀聯閤多奈哌齊治療AD能更有效改善AD患者的認知功能和日常生活能力,效果優于單獨使用多奈哌齊.
목적 탐토불동류형타정류약물연합다내고제치료아이자해묵병적료효.방법 장AD환자90례채용수자표법수궤분위타정A조(아탁벌타정+다내고제치료)31례、타정B조(신벌타정+다내고제치료)27례、다내고제조(단용다내고제치료)32례.삼조료정균위1년.재용약전후분별대삼조환자적혈지수평[담고순(CH)화저밀도지단백담고순(LDL-C)]진행검측화비교,진행간역정신상태량표(MMSE)、일상생활능역량표(ADL)급전면쇠퇴량표(GDS)적검측화평분,통계분석검측결과차이.결과 치료후다내고제조MMSE、ADL급GDS평분분별위(17.00±2.99)분、(60.44±14.57)분、(4.28±1.22)분,균차우타정A조적[(19.90±3.07)분、(71.61 ±18.50)분、(3.39±1.15)분](t=0.218,P＜0.05,t=2.669,P＜0.01,t=2.562,P＜0.01)화타정B조적[(19.88 ±6.66)분、(71.89±19.61)분、(3.37±1.39)분](t=1.959,P＜0.05,t =2.991,P ＜0.01,t =2.265,P＜0.01).결론 타정연합다내고제치료AD능경유효개선AD환자적인지공능화일상생활능력,효과우우단독사용다내고제.
Objective To explore the effect of different types of statins combined with donepezil in the treatment of Alzheimer disease(AD).Methods According to the digital table,90 patients with AD were randomly divided into the statins A group(atrovstatin combined with donepezil) 31 cases,statins B group(simvastatin combined with donepezil)27 cases,and donepezil group(only with donepezil) 32 cases.All patients were treated for one year.The blood lipid level (including cholesterol (CH) and low density lipoprotein cholesterol (LDL-C),mini-mental state examination(MMSE),activity of daily living(ADL) and global deterioration scale (GDS) were detected and compared respectively among groups before and after treatment.Results The MMSE,ADL and GDS scores of the donepezil group were (17.00 ± 2.99) points,(60.44 ± 14.57) points,(4.28 ± 1.22) points,respectively,which were worse than those of the statins A group [(19.90 ± 3.07) points,(71.61 ± 18.50) points,(3.39 ± 1.15) points] (t =0.218,P ＜ 0.05,t =2.669,P ＜ 0.01,t =2.562,P ＜ 0.01) and statins B group [(19.88 ± 6.66) points,(71.89 ± 19.61) points,(3.37 ±l.39)points](t=l.959,P ＜0.05,t=2.991,P ＜0.0l,t=2,265,P ＜0.01).Conclusion The combination of donepezil and statins can effectively improve cognitive function and daily living ability in patients with AD,and its effect is superior to single use of donepezil.
